AlphAIalphai — Financial news for AI agents
gurufocus.comSEP 23 min read$RVMD

RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM

Revolution Medicines (RVMD) announced the publication of Phase 1/2 trial results for RASONQUE in the New England Journal of Medicine. The data showed promising efficacy and safety in treating advanced RAS mutant NSCLC. The company has a market cap of $44.85 billion and is currently unprofitable, with a high Price-to-Sales ratio of 70.5x. Insider activity shows significant selling, while guru ownership trends are mixed.

Original reporting
gurufocus.com
Published Sep 2, 2026, 10:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$RVMD
Bullish
high confidence
Mentioned
$RVMD
Relevance
9/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$RVMDBullishMed
01

Why it matters

The NEJM publication provides the first robust efficacy read‑out for RASONQUE in NSCLC, a key pipeline asset.

02

Market read

Positive trial data could catalyze a price move for RVMD and influence sentiment toward RAS‑targeted therapies.

03

What to watch

Insider selling and high valuation multiples may temper upside despite the data.

Relevance 9/10Novelty 9/10Timing: today

Background

Revolution Medicines (RVMD) is a clinical‑stage biotech focused on RAS‑driven cancers; the company has no product revenue and relies on trial milestones.

Company-level read

Ticker impact

$RVMDBullishHigh confidence
Context

Phase 1/2 trial results for RASONQUE (daraxonrasib) were published in NEJM, showing a 42% confirmed response rate and 8.3‑month median PFS.

Expected impact

Potential short‑term upside of 5‑10% as investors price in the trial success.

Evidence & confidence

First report of robust efficacy in a heavily pre‑treated NSCLC cohort; data are fresh and material for a clinical‑stage biotech.

Market effects

Sector

Strengthens the RAS‑inhibitor niche and may boost peer biotech valuations.

Regional

US biotech sector may see modest gains on the back of the data.

Global

Highlights progress in targeted oncology, relevant to global pharma investors.

Counterpoint

What could challenge this read

The trial size is modest and safety signals remain, so the rally could be limited.

Key entities

  • company
    Revolution Medicines Inc

    Biotech developing RAS inhibitors, ticker RVMD.

  • drug
    RASONQUE (daraxonrasib)

    Oral multi‑selective RAS inhibitor evaluated in Phase 1/2 trial.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 4
$RVMDHighAI 8/10

Michael Osterholm Says He's Staying Four More Years as Public Health's Systems Buckle — BigGo Finance

Revolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.

finance.biggo.com2 min
SEP 3
$RVMDHighAI 9/10

Daraxonrasib shrinks tumours in one-third of lung cancer patients

Revolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting

mugglehead.com2 min
SEP 3
$RVMDMedAI 8/10

RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

Revolution Medicines (RVMD) presented updated Phase 1/2 trial data for Rasonque in non-small cell lung cancer (NSCLC), showing a 42% overall response rate, 8.3-month median progression-free survival, and 16-month median overall survival. Truist Securities noted the results support RVMD's Phase 3 lung cancer study. Rasonque was recently FDA-approved for pancreatic cancer, with Phase 3 results expected in December 2027 for NSCLC.

biospace.com2 min
SEP 3
$RVMDMedAI 8/10

NEJM publishes daraxonrasib NSCLC data supporting Phase III program

Revolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.

allsci.com2 min
SEP 2
$RVMDHighAI 9/10

Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC

Revolution Medicines (RVMD) announced NEJM publication of Phase 1/2 trial data for RASONQUE (daraxonrasib) in RAS mutant NSCLC. The trial showed 42% objective response rate and 89% disease control rate in a subgroup, with manageable safety profile. The data support the ongoing Phase 3 RASolve 301 trial, following recent FDA approval for pancreatic cancer.

quiverquant.com3 min